<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190229</url>
  </required_header>
  <id_info>
    <org_study_id>P011014</org_study_id>
    <nct_id>NCT00190229</nct_id>
  </id_info>
  <brief_title>Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura</brief_title>
  <official_title>CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Henoch-Schonlein purpura is a leucocytoclastic systemic vasculitis involving small vessels
      with the deposition of immune complexes containing IgA. It is characterized by the
      association of skin, joint and gastrointestinal manifestations. Even though the evolution is
      usually simple, some patients, especially adults, may have severe visceral involvement
      including heart, lung, brain and renal disease. The best treatment is currently unknown. This
      study will test the safety and efficacy of steroids associated or not with cyclosphosphamide
      to treat the acute lesions and to prevent the development of chronic lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The protocol test the role of 2 modalities of treatment (steroid vs. steroid and
      cyclophosphamide) for severe systemic form of Henoch-Schonlein purpura. The severe forms
      include extracapillary glomerulonephritis, myocarditis, pneumonitis, occult involvement,
      severe gastro-intestinal bleeding. No other randomized trial has been performed in adult
      patient for this indication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birmingham Vasculitis Activity Score (BVAS)</measure>
    <time_frame>during de study</time_frame>
    <description>Birmingham Vasculitis Activity Score (BVAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic lesions (Vasculitis Damage Index)</measure>
    <time_frame>during the study</time_frame>
    <description>Chronic lesions (Vasculitis Damage Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function at 12 months</measure>
    <time_frame>during the study</time_frame>
    <description>Renal function at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney survival at 12 months</measure>
    <time_frame>during the study</time_frame>
    <description>Kidney survival at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival at 12 months</measure>
    <time_frame>during the study</time_frame>
    <description>Patient survival at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>during th study</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections</measure>
    <time_frame>during the study</time_frame>
    <description>Infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to steroid or cyclophosphamide</measure>
    <time_frame>during the study</time_frame>
    <description>Adverse events related to steroid or cyclophosphamide</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Henoch-Schoenlein Purpura</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Henoch-Schoenlein purpura

          -  Patient's age &gt; 18 years

        Exclusion criteria:

          -  Patient presenting a purpura RHEUMATOID the diagnosis of which is confirmed by the
             histology presenting at least a visceral infringement(achievement) making consider the
             affection as engraves(burns)

          -  of 18 or more years old Patient

          -  Patient capable of understanding(including) the advantages and the risks of the try

          -  Patient having given his assent lit in writing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric THERVET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital LARIBOISIERE</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schönlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002 May;13(5):1271-8.</citation>
    <PMID>11961015</PMID>
  </results_reference>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Amel OUSLIMANI</name_title>
    <organization>Department Clinical Research of developpement</organization>
  </responsible_party>
  <keyword>Vasculitis</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Schoenlein-Henoch</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

